# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Outlook for 2024 For fiscal year 2024, the Company reaffirmed full year revenue guidance, which is expected to be in the ra...
Standard BioTools (NASDAQ:LAB) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(...
The restructuring plan is expected to generate annualized operating expense savings of $45 million to $50 million in fiscal 202...
TD Cowen analyst Daniel Brennan initiates coverage on Standard BioTools (NASDAQ:LAB) with a Buy rating and announces Price T...